Key result
Bendroflumethiazide plus captopril reduces glucose infusion rates ~27% vs captopril alone, worsening insulin action.
Why the study?
Does captopril combined with low-dose bendroflumethiazide reduce insulin sensitivity compared to captopril alone in hypertensive Type 2 diabetic patients?
RCT (n=15)
double-blind
randomised
Does captopril combined with low-dose bendroflumethiazide reduce insulin sensitivity compared to captopril alone in hypertensive Type 2 diabetic patients?
Absolute Event Rate: 25.1% vs 34.2%
p-value: p=< 0.01
The addition of low-dose bendroflumethiazide to captopril in hypertensive patients with Type 2 diabetes lowers blood pressure further but causes deleterious effects on insulin sensitivity.
Warrants caution adding low-dose bendroflumethiazide to captopril in hypertensive T2DM; confirms adverse metabolic effects of this combination on insulin sensitivity.
AIMS: To establish the safety in terms of insulin sensitivity of a low dose thiazide/ACE inhibitor combination. METHODS: We examined the effects on insulin sensitivity of captopril either alone or in combination with low-dose bendroflumethiazide (1.25 mg) in 15 hypertensive Type 2 diabetic patients. Insulin action was assessed using an isoglycaemic hyperinsulinaemic clamp in a double-blind, randomised, crossover study after a 6-week placebo run-in and following two 12-week treatment periods with captopril (C) (100 mg) alone or in combination with bendroflumethiazide (CB) (1.25 mg). RESULTS: Blood pressure was lower following CB compare to C (138/83 vs. 144/85 mmHg; P < 0.05) and both were lower than baseline (153/92 mmHg; P < 0.01). CB resulted in a significant increase in fasting plasma glucose compared to C (9.6 +/- 2.6 vs. 8.5 +/- 1.6 mmol/l; P < 0.05). Exogenous glucose infusion rates required to maintain isoglycaemia during hyperinsulinaemia were lower after CB compared to C (25.1 +/- 13.3 vs. 34.2 +/- 16.8 micromol/kg/min; P < 0.01) as were isotopically determined glucose utilisation rates (29.0 +/- 12.4 vs. 36.6 +/- 17.3 micromol/kg/min; P < 0.05). There was no significant difference in fasting endogenous glucose production between treatments (CB 9.3 +/- 3.3 vs. C 8.6 +/- 1.6 micromol/kg/min), nor between suppression following insulin (CB 4.0 +/- 2.1 vs. C 4.3 +/- 3.1 micromol/kg/min). CONCLUSIONS: Combination of low-dose bendroflumethiazide with captopril lowered blood pressure but resulted in deleterious effects on insulin action compared to captopril alone.
No takes yet. Share an insight, caveat, or question.
McLaughlin et al. (2008) conducted an RCT in Hypertension and Type 2 diabetes (n=15). Captopril and bendroflumethiazide vs. Captopril 100 mg alone was evaluated on Exogenous glucose infusion rates required to maintain isoglycaemia during hyperinsulinaemia (p=< 0.01). Combination of low-dose bendroflumethiazide with captopril reduced exogenous glucose infusion rates compared to captopril alone (25.1 vs 34.2 micromol/kg/min; P<0.01), worsening insulin action.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: